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Abstract This review aims to discuss the current state-of-
the-art of sentinel node (SN) mapping in urological
malignancies. The principles and methodological aspects
of lymphatic mapping and SN biopsy in urological
malignancies are reviewed. Literature search was restricted
to English language. The references of the retrieved articles
were examined to identify additional articles. The review
also includes meta-analyses published in the past 5 years.
SN biopsy for penile cancer is recommended by the
European Association of Urology as the preferred staging
tool for clinically node-negative patients with at least T1G2
tumours (level of evidence 2a, Grade B). The feasibility of
SN biopsy in prostate cancer has been repeatedly demon-
strated and its potential value is increasingly being recog-
nised. However, conclusive prospective clinical data as
well as consensus on methodology and patient selection are
still lacking. For bladder, renal and testicular cancer, only
few studies have been published, and concerns around high
false-negative rates remain. Throughout the years, the uro-
oncological field has portrayed a pivotal role in the
development of the SN concept. Recent advances such as
hybrid tracers and novel intraoperative detection tools such
as fluorescence and portable gamma imaging will
hopefully encourage prospectively designed clinical trials
which can further substantiate the potential of the SN
approach in becoming an integral part of staging in uro-
logical malignancies beyond penile cancer.
Keywords Sentinel node  Urology  Urological
malignancies  Penile cancer  Prostate cancer  Bladder 
Renal cancer  Testicular cancer  Lymphatic drainage 
SPECT/CT
Introduction
A sentinel node (SN) is defined as any lymph node on a
direct drainage pathway from the primary tumour. This
definition reflects the physiology of lymphatic drainage and
the stepwise dissemination of cancer to a regional lymph
node basin; it also acknowledges the possibility that more
than one lymph node can be directly connected with the
tumour and thus be a potential first site to harbour metas-
tases before further progression to so called higher-tier/
higher-echelon nodes [1]. With the introduction of the SN
concept, a minimally invasive diagnostic modality
emerged for early detection of occult lymph node metas-
tases. Since its introduction more than 20 years ago for
melanoma and breast cancer, the SN procedure has gone
through a major development process and has become an
essential component of lymph node staging in penile can-
cer [2, 3]. Consequently, this has led to an increasing
interest in the application of the SN concept in other uro-
logical malignancies. Although both preoperative lym-
phatic mapping and intraoperative SN detection are
common parts of the SN procedure for urological tumours,
injection techniques and lymphatic drainage patterns may
differ. In penile cancer, lymphatic drainage is mainly
& O. R. Brouwer
O.R.Brouwer@lumc.nl
1 Department of Urologyand Interventional Molecular Imaging
Laboratory, Leiden University Medical Center, Albinusdreef
2, 2333 ZA Leiden, The Netherlands
2 Interventional Molecular Imaging Laboratory, Department of
Radiology, Leiden University Medical Center, Albinusdreef
2, 2333 ZA Leiden, The Netherlands
3 Department of Urology, The Netherlands Cancer Institute—
Antoni van Leeuwenhoek Hospital, Plesmanlaan 121,
1066 CX Amsterdam, The Netherlands
123
Clin Transl Imaging (2016) 4:395–410
DOI 10.1007/s40336-016-0189-4
superficial and the first draining lymph nodes are usually
located in the groin. In contrast, lymphatic drainage in
prostate cancer and other urological tumours is deep and
SNs are often found along the iliac vessels as well as in
other complex anatomical areas (Fig. 1). This article cov-
ers the principles and methodological aspects of lymphatic
mapping and SN biopsy in urological malignancies. The
original introduction and evolution of the SN procedure in
penile cancer is reviewed, as well as its potential role in
prostate, bladder, renal and testicular cancer.
Methods
An extensive literature search was performed based on the
following PubMed/MEDLINE medical subject headings:
SN biopsy, lymphatic mapping, SPECT/CT, intraoperative
SN detection, hybrid tracer, penile cancer, prostate cancer,
bladder cancer, testicular cancer and renal cell carcinoma.
The search was restricted to English language. The refer-
ences of the retrieved articles were examined to identify
additional articles. Meta-analyses published in the past
5 years were also included.
Penile cancer
Evolution and guideline recommendations
Penile cancer is a relatively rare disease in the western
world, with an incidence of approximately 1 per 1,00,000
[4]. Penile cancer only rarely presents distant metastases
without spreading via the lymphatic system to the inguinal
regions first. As a consequence, the presence of lymph
node involvement is the single most important prognostic
factor for cancer-specific death [5]. At present, currently
available non-invasive staging techniques lack sufficient
accuracy to reliably stage the nodal status in patient with
penile cancer which is why surgical staging remains
indispensable. However, a complete inguinal lym-
phadenectomy is associated with substantial morbidity.
Since only 20–25 % of clinically node negative patients
harbour occult nodal metastasis, performing a complete
lymphadenectomy is unnecessary overtreatment in
75–80 % of patients [6]. It is because of the abovemen-
tioned reasons that penile cancer has been an ideal model
for the development of the SN concept. In 1977, it was the
Paraguayan urologist Ramon Caban˜as who was the first to
publish a study using lymphangiograms to locate the pri-
mary draining lymph nodes followed by excision of these
nodes [7]. In other words, Caban˜as was the first investi-
gator to perform lymphatic mapping followed by SN
biopsy. However, Caban˜as described the SN as to be
localised in a fixed, predetermined location, not taking into
account possible individual variations in lymphatic drai-
nage patterns. Furthermore, Caban˜as did neither use blue
dye, radiotracers, lymphoscintigraphy nor a gamma probe,
which made his method difficult to reproduce. Approxi-
mately 15 years later, the SN concept re-emerged outside
the field of urology when Morton et al. performed SN
biopsy in melanoma patients using radiocolloid and blue
dye to intraoperatively visualise the lymphatic vessels and
subsequently localise the SN [8]. This landmark study was
the first to recognise variability in lymphatic drainage and
SN location, which paved the way for further development
of the approach. Based on this modernised concept, the SN
procedure was re-introduced in uro-oncology in 1994 when
Horenblas et al. initiated studies in the Netherlands
applying the SN biopsy in its current form in penile cancer
patients [9]. Since then, the procedure has evolved into a
reliable staging technique, with a low complication rate
compared to (prophylactic) inguinal lymphadenectomy
[10–12].
Fig. 1 Anatomical sentinel node (SN) distribution. In penile cancer
(a) SNs are limited to the groin and are predominantly found in the
superior and central inguinal Daseler’s zones [28]. In contrast,
prostate cancer (b) SN locations concern different pelvic basins
(white caption) according to Wawroschek F et al. [65] as well as in
other less common sites (green captions) according to Meinhardt W
et al. (Prostate Cancer 2012;2012:751–3)
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The introduction of SN biopsy has also led to a signif-
icant improvement in mortality of patients with penile
cancer. A recent study evaluated the 5-year cancer-specific
survival of patients with squamous cell carcinoma of the
penis. They compared the 5-year cancer survival rate
before and after the introduction of SN biopsy and found a
statistically significant difference, 91 % compared to 82 %
(p = 0.021). This finding is most likely due to the detec-
tion of microscopic disease by SNB, resulting in early
lymph node dissection in patients with a tumour-positive
SN [13].
SN biopsy for penile cancer entered the European
Association of Urology guidelines in 2009 as the preferred
staging tool for clinically node-negative patients (defined
by ultrasound-guided fine needle cytology) with at least
T1G2 tumours (level of evidence 2a, Grade B) and the
procedure is now standard of care in many (specialised)
centres [3].
Methodological aspects
For penile cancer, there is a reasonable consensus regard-
ing the preoperative lymphatic mapping procedure. The
most widely applied radiocolloid (in Europe) is
99mTechnetium-nanocolloid which is generally injected
intradermally within 1 cm radius proximally from the pri-
mary tumour or from the surgical scar in case of prior
primary lesion excision. A total tracer dose of 50–90 MBq
in 0.2–0.4 cc volume divided in three sites is injected
[14, 15]. The technique is also feasible after removal of the
primary penile tumour by, e.g., partial penectomy (in this
case the tracer is injected at the base of the penis), allowing
for rapid removal of the primary tumour where needed and
subsequent SN dissection in a specialised centre in a sep-
arate session [16]. Recently, this approach has successfully
been applied in a series of 92 patients [17]. The evolution
of the SN procedure throughout the years has led to a SN
identification rate of 97 % with an acceptable false-nega-
tive rate of 7 % [18]. Repeat SN biopsy after tumour
recurrence is also a validated procedure [19]. Lym-
phoscintigraphy after radiocolloid injection is mostly per-
formed at 10–20 min and 2 h postinjection [12, 15]. The
most frequently visualised lymphatic drainage pattern is
bilateral drainage to both groins (80 %) and this technique
has a reproducibility rate of 100 % [20]. In case of non-
visualisation or unilateral drainage, tracer re-injection can
be performed [21]. Some centres add single-photon emis-
sion computed tomography-computed tomography
(SPECT/CT) to the imaging protocol to provide additional
anatomical information of the SNs. For instance, the
modality can differentiate inguinal from iliac (most fre-
quently second-echelon) lymph nodes and is also helpful to
detect additional SNs (Fig. 2) [22]. Furthermore, SPECT/
CT has been used to optimise the procedure and to analyse
the lymphatic drainage of penile cancer by evaluating the
possible implications for the extent of inguinal lymph node
dissection. In 50 patients lymphatic drainage was visu-
alised in 82 of 86 clinically node-negative groins (95 %)
scheduled for the SN procedure. All SNs were located in
the inguinal zones (medial superior 73 %, lateral superior
8.7 % and central 18.3 % on SPECT/CT (Fig. 1a). No
lymphatic drainage to the inferior zones of the groin was
seen which suggests the possibility to exclude these zones
from a subsequent inguinal lymph node dissection in the
case of a tumour-positive SN [23].
As is customary for SN biopsy in melanoma and breast
cancer, intraoperative SN detection is guided by a gamma-
ray detection probe and blue dye. The entire (pre- and
intraoperative) procedure can be performed in both 1- and
2-day protocols, although a 1-day protocol may yield lower
false-negative rates [12]. Proper pathological node exami-
nation is imperative to minimise false-negative results. As
stated in the EAU guidelines, additional inguinal node
dissection is recommended in all men with nodal metas-
tases at SN biopsy [3].
Refinements and future prospects
Initially, the most significant drawback of SN biopsy for
penile cancer was found to be a relatively high false-neg-
ative rate (22 %) [24]. After analysis of the false-negative
cases, several modifications were made to the procedure to
decrease the false-negative rate and thus increase sensi-
tivity: (1) histopathologic analysis was expanded with
serial sectioning of the harvested SNs; (2) preoperative
ultrasound of cN0 groins with fine needle aspiration
cytology of suspicious lymph nodes was introduced and (3)
exploration of the groin in the case of non-visualisation
during scintigraphy was added, including intraoperative
palpation of the wound to identify suspicious lymph nodes
that failed to pick up any radiocolloid (due to tumour
blockage) [25]. Thanks to these modifications, the proce-
dure has evolved into a reliable minimally invasive staging
technique, with an associated sensitivity of 93–95 % and
low morbidity in experienced centres [10, 26]. However,
higher false-negative rates have also been reported, a
recent study stating a figure as high as 15 % and a later
meta-analysis showing pooled sensitivity rates of 88 %
[27, 28]. Accurate staging with SN biopsy can only be
achieved if all nodes on a direct drainage pathway from the
tumour are harvested. If SNs are left behind, this consti-
tutes one of the potential causes for false-negative results.
The following developments have refined the procedure
and, in time, may help minimise false-negative rates. Pre-
operative imaging using SPECT/CT was shown to improve
inguinal detection of SN by providing superior 3D
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information on lymph node location as compared to con-
ventional scintigraphy imaging [22, 23, 25]. The integra-
tion of a portable gamma camera during the intraoperative
procedure may also increase the detection sensitivity, since
it provides an intraoperative overview image of the
radioactive SNs and enables post-excision confirmation of
complete removal of all SNs [29]. As mentioned before,
the most widely used tracer for intraoperative optical
detection of the SN and its afferent lymphatic duct is blue
dye. The visualisation rate of lymph nodes with blue dye
alone is between 55 and 70 % [29, 30]. In recent years,
near-infared (NIR) imaging has become available as an
additional optical guidance modality. Fluorescent tracers in
the NIR spectrum of light provide the benefit of visuali-
sation of lymph drainage without obscuring the surgical
field in the white light surgical setting. Indocyanine green
(ICG) is the most frequently used fluorescent dye that can
be visualised using NIR imaging systems [31]. When
injected locally, ICG rapidly migrates through the lym-
phatic system enabling intraoperative visualisation of
lymphatic ducts and nodes, yet these quick migrational
properties may also result in a limited diagnostic time
frame and the visualisation of higher echelon nodes [32].
To solve this limitation, a recent development in penile
cancer SN biopsy has been the introduction of a hybrid
tracer molecule, comprised of the fluorescent dye ICG
covalently attached to the 99mTc nanocolloid [33]. This
hybrid tracer molecule combines the properties of both
modalities in one compound and can thus be used to
provide both preoperative SPECT imaging and intraoper-
ative fluorescence guidance during surgery [34]. The tracer
demonstrated favourable characteristics compared to blue
dye, allowing intraoperative visualisation of 96.8 % of SNs
compared to blue dye which stained just 55.7 % [29].
Prostate cancer
Concept and potential indications
Prostate cancer is the most frequent urogenital malignancy
and the second most common cause of death by cancer in
males [35]. Since prostate cancer may initially metastasize
to the lymph nodes, lymph node staging is important for
both prognosis and therapeutic management. For instance,
the presence of lymph node metastases can disqualify
patients from local therapy with curative intent, such as
radical prostatectomy or external beam radiation therapy,
and result in treatment with androgen-deprivation therapy
instead [36]. Therefore, accurate lymph node staging in
prostate cancer is imperative. To date, none of the available
non-invasive diagnostic imaging modalities provide a
reliable assessment of lymph node (micro) metastases; this
is the principal reason why open or laparoscopic lym-
phadenectomy is still considered the gold standard for
regional lymph node staging. Predictive nomograms are
generally used to define the indication for a nodal dissec-
tion [37–40], and European guidelines recommend nodal
dissection when nomograms predict a risk of more than
Fig. 2 Lymphatic mapping in
penile cancer. Planar anterior
image a showing drainage to
two lymph nodes in the right
groin and faint left inguinal
uptake. By contrast, coronal
(b) and transversal (c) fused
SPECT/CT show clear uptake in
the left groin corresponding to
two lymph nodes (circle) along
both sides of the femoral vessels
as seen on CT (d). Note that
intense uptake in the right groin
corresponds with a cluster of
four lymph nodes (circle)
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5 % on the presence of nodal metastases (intermediate and
high-risk patients) [35, 37].
When performing a lymphadenectomy, an extended
pelvic lymph node dissection template is advised, because
dissection limited to the obturator fossa misses approxi-
mately 50 % of metastases [35]. Apart from its role in
discriminating N0 from N1 patients, recent retrospective
data suggest that an extended lymphadenectomy also has
therapeutic value: in[300 pN1 prostate cancer patients,
removal of less than 14 nodes resulted in poorer outcome
when compared to removal of more lymph nodes [41]. On
the other hand, an extended nodal dissection is associated
with considerable morbidity, and complications of the
procedure are strongly correlated with the number of nodes
removed, ranging from 10.5 % for 1–5 lymph nodes to
24.3 % when dissection includes more than 20 lymph
nodes [42].
Despite extended nodal dissection, pelvic recurrences do
occur, and the false-negative rate of extended pelvic nodal
dissection for prostate cancer was estimated to be around
12.5 % [43, 44]. This can potentially be explained by the
finding that tumour-positive (sentinel) nodes may be pre-
sent outside the extended pelvic node dissection template in
[5 % of patients. With the aim to ‘‘remove the nodes that
count, rather than count the nodes that don’t’’ [45], SN
biopsy has emerged as an alternative staging procedure.
The potential advantages of SN biopsy are a lower inci-
dence of complications and the possibility of identifying
tumour-draining lymph nodes outside the field of an
extended lymphadenectomy [46]. If the goal is to remove
as many (tumour-positive) nodes as possible to maximise a
potential therapeutic effect, SN biopsy may be combined
with an extended lymph node dissection [47, 48].
SN biopsy is generally reserved for patients in the
intermediate-risk group (clinical stage T2b-c, PSA
10–20 ng/mL, Gleason 7) where it can identify lymph node
metastases in 20 % of patients on average. Nevertheless,
SN biopsy has been able to identify metastases in as many
as 7–10 % of patients with more favourable risk factors
[43]. In the intermediate-risk group, a pooled sensitivity
rate of 95 % can be reached as reported by meta-analyses
[49, 50]. The sensitivity appears to decrease to 76 % in
high-risk patients [51].
As mentioned above, the presence of tumour-bearing
lymph node(s) may influence the choice between local
(curative) treatment of the prostate or hormonal therapy in
patients in the intermediate-risk group. Another possible
indication is to select patients who are eligible for salvage
treatment of the prostate (in case of biochemical recurrence
after local treatment). Selecting these patients is challenged
by the fact that the usual parameters to stratify patients in
risk groups do not apply to patients with intraprostatic
recurrence. Since salvage treatment of the prostate may
result in serious complications, it should only be consid-
ered when the prostate is actually the only tumour-bearing
site [36].
At present, the European Association of Urology
guidelines deem the SN procedure in prostate cancer at an
experimental state due to lack of larger prospective studies
and higher level of evidence. Nevertheless, guidelines
acknowledge the potential role of the SN approach in
defining lymph node dissection templates [35].
Methodological aspects
Tracer injection to identify SNs in prostate cancer is dif-
ferent compared to the technique used with other malig-
nancies where the location of the primary tumour is often
visible or palpable. In those cases, a well-directed peri- or
intratumoural injection can be placed to observe the lym-
phatic drainage of the tumour. In prostate cancer, however,
it is not known from which part of the organ the metastatic
spread originates. Therefore, the aim of lymphatic mapping
in prostate cancer has traditionally been to visualise all
primarily draining lymph nodes (SNs).
Most studies use a transperineal or transrectal tracer
injection method which is generally guided by ultrasound.
One study described intraoperative optical tracer injection
transperitoneally but in general, preoperative injection is
used [52–54]. When the transrectal injection route is used
prophylactic antibiotics are given to prevent infections.
Injections are traditionally placed in both lobes in the
peripheral zone of the prostate, since this is where most
tumours (approximately 80 %) reside. However, tracer
distribution may show considerable variation, which was
recently demonstrated by Buckle et al. [55]. With the
introduction of MRI-guided injection techniques, ongoing
studies should reveal whether intratumoural injection is
superior to several tracer depots within the entire prostate
[56].
The most frequently used radiopharmaceutical in Eur-
ope has been 99mTc-nanocolloid. However, technetium-
99m can also be bound to sulphur or phytate as used in
other continents [57, 58]. In literature studies particle sizes
vary (80–1500 nm) as well as the amount of radioactivity
injected (60–250 MBq) [59]. The particle concentration
also appears to be important, and the use of a reduced
labelling dilution volume (0.4 mL 99mTc per 0.2 mg
nanocolloid) yields more visualised SNs with higher
radioactivity count rates [60]. No comparative studies are
available on the optimal dose and injection volume as of
yet.
Lymphoscintigraphy is mostly acquired 15 min after
radiocolloid administration, which visualises the first
draining lymph nodes in almost 88 % of cases [53].
Delayed imaging may be performed 2–4 h after injection
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(increasing the visualization rate to 90–95 %). Comparing
the early and delayed images enables differentiation of
second-echelon lymph nodes from SNs. Additional hybrid
imaging with SPECT/CT enables anatomical localisation
of SNs which can aid in planning the surgical procedure
[44]. SPECT/CT was shown to increase the SN visualisa-
tion rate from 91 % for planar scintigraphy to 98 %.
SPECT/CT also depicted more SN than planar images
(average 4.3 versus 2.2 SNs) in 46 patients; 44 % of the
SNs containing metastases were visualised only by SPECT/
CT [61].
Intraoperatively, the radioactive SNs can be detected
with a gamma-ray detection probe. Both open and
laparoscopic approaches have been extensively studied in
prostate cancer although there is a shift toward the less
invasive laparoscopic and robot-assisted techniques
[48, 62, 63].
Review of the results
The SN procedure for prostate cancer was introduced by
the Augsburg group in 1999 [64]. SN biopsy was based on
an open surgery approach with the use of a gamma probe to
guide detection of the radioactive sentinel nodes. Initially,
to evaluate the sensitivity of the procedure, an extended
lymph node dissection was performed (common iliac,
external iliac, obturator, internal iliac and presacral
regions). After the initial feasibility report, the studied
cohort was gradually expanded to a total of 638 patients,
demonstrating an overall sensitivity of 97 % [65]. The
most frequently occurring SN location was the internal
iliac region (32 %), followed by the external iliac region
(29 %) and obturator fossa (26 %, Fig. 1). The pioneering
Augsburg group laid the groundwork for others to explore
the SN approach for prostate cancer, reporting varying
outcomes. In total, over 7000 cases were reported in the
literature [66–68]. Overall, the median number of excised
SNs was 6 (range 2–26) per patient. The SN detection rate
ranged 76–100 % [46, 52, 54, 66, 67, 69–75]. In 4.1–25 %
of patients, SNs outside the extended dissection template
were found, whereas 3.5–17 % of patients with positive
LNs had SN metastases outside the extended dissection
template. In these studies, the median percentage of
patients with positive LNs was 20.4 % (range 4.7–50) with
a false-negative rate of 1 % (range 0–20), respectively,
[44, 46, 52, 57, 64, 67, 70–82]. The largest study was
performed by Holl et al. and published in 2009. Out of
more than 2000 patients evaluated, only 11 false-negative
cases (5.5 %) were reported [67]. A recent meta-analysis
reported a pooled detection rate of 94 % (89–96.6 %) and a
pooled sensitivity rate of 95 % (92–97 %) [49]. The
potential advantages of the SN approach are a lower inci-
dence of complications and the possibility of identifying
tumour-draining lymph nodes outside the extended dis-
section field. Despite the relatively high sensitivity rates
reported throughout the years, the routine use of SN biopsy
in prostate cancer is still topic of debate as high level
evidence from large prospective studies is still lacking.
Recently, a large study by Abdollah et al. reported that
removing a higher number of (tumour-positive) lymph
nodes may improve cancer-specific survival rates [41].
This might support combining extended lymphadenectomy
with SN mapping to prevent missing potentially relevant
nodes which reside outside the extended dissection field.
Refinements and future prospects
Accurate localisation of SNs in the pelvis can be chal-
lenging. The introduction of SPECT/CT has refined pre-
operative lymphatic mapping by allowing exact
pinpointing of the localisation of the SNs and providing
anatomical reference points whilst planning the surgical
procedure. SPECT/CT was shown to be able to identify
SNs outside the extended dissection in 31 % of cases
[46, 61]. The aberrantly located SNs were located proximal
to the most distal part of the aorta, in the vicinity of the
common iliac artery (above the crossing of the ureter),
around the inferior mesenteric vessels, in the perivesical
area and near the umbilical ligament.
Currently, the intraoperative procedure is generally
carried out using a minimally invasive (laparoscopic and
robot-assisted) approach. During laparoscopic surgery, the
urologist traditionally localises an SN under guidance by
the sound pitch originated by the laparoscopic gamma-
probe. However, intraoperative spatial orientation using
this device can sometimes be cumbersome, as a laparo-
scopic probe does not provide visual information. A par-
ticular innovation in the SN procedure for prostate cancer
has been illustrated in recent years by the use of
portable gamma to intraoperatively provide a two-dimen-
sional image of the radioactive SNs (Fig. 3). The imaging
system was shown to aid in confirmation of accurate SN
removal in the laparoscopic setting [82, 83]. Current
portable gamma cameras are capable of detecting two
different signals: the signal of 99mTc-nanocolloid for the
visualisation of SNs, plus the signal of an iodine-125 (125I)
seed pointer placed on the tip of the laparoscopic gamma-
ray detection probe. The ‘‘hot’’ tip of the probe can be
moved to the hot node, guided by the image of the
portable camera (Fig. 3). This approach helps navigate
towards the location of the SNs. Recent studies have also
explored using the preoperatively acquired SPECT/CT
images for intraoperative navigation (virtual/mixed reality)
[84, 85].
In recent years, fluorescent dyes are increasingly being
used during SN dissection in prostate cancer. These tracers
400 Clin Transl Imaging (2016) 4:395–410
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are also injected intraprostatically and allow for realtime
visualization of SNs and their afferent lymphatic vessels.
One of the benefits of this approach can be that whereas
intraoperative SN localisation using radiocolloid-based
techniques can sometimes be hampered when SNs are
located near the prostatic injection site (because of the high
radioactive background signal), fluorescence-based tech-
niques do not suffer from this limitation due to the rela-
tively high resolution of fluorescence imaging systems. The
most frequently used fluorescent dye has been ICG [86].
Using ICG in its free form has the benefit of rapid
migration into the lymph nodes draining the prostate after
intraprostatic injection [87]. Retention of tracer in lymph
nodes, however, is much lower than with the use of
nanocolloid bound ICG. Therefore, injection of free ICG is
applied briefly (10–30 min) prior to the nodal dissec-
tion. This may provide logistical benefits compared to
radiocolloid based tracing (no radioactivity, no preopera-
tive scans), which may partially explain its increasing
popularity [54]. However, although free ICG seems to
provide a practical alternative gamma tracing, it does not
allow for preoperative SPECT/CT and as a consequence,
alternative lymph draining patterns may be missed due to
the low penetrance of the NIR signal of ICG [88]. Studies
using ICG bound to nanocolloid have also been performed
and have shown to retain the properties of the original
radiocolloid exhibiting longer retention times in the lymph
nodes and allowing for combined pre- and perioperative
imaging in open/laparoscopic procedures (Fig. 4)
[34, 48, 75].
Another recent development is the use of ultrasmall
superparamagnetic nanoparticle MRI [89–91]. A handheld
magnetometer was used to detect intra-prostatically injec-
ted superparamagnetic iron oxide in 20 men with prostate
cancer. Metastases were found only in lymph nodes
detected using the magnetometer and identified as SNs in
this analysis [91]. The role of this new approach for
intraoperative detection of lymphatic drainage patterns
holds promise but needs further evaluation.
Other malignancies
Bladder cancer
In the United States, bladder cancer is the fourth most
common type of cancer in men and the ninth most common
cancer in women [92]. Lymph node metastases are com-
mon in patients with (muscle-invasive) bladder cancer, and
Fig. 3 Sentinel node
localisation in prostate cancer
after administration of 99mTc-
nanocolloid. Coronal volume
rendering (a) and transversal (b,
c) SPECT/CT showing two
sentinel nodes along the left
common iliac artery. Based on
this anatomical information
both nodes are subsequently
removed (d) laparoscopically,
guided by a portable gamma
camera (e)
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the presence of lymph node metastases, their number and
the volume of involved nodes are strongly associated with
survival [93, 94]. Therefore, dissection of tumour-positive
nodes may confer a survival benefit in patients with mus-
cle-invasive bladder cancer with lymph node metastases,
which is supported by studies comparing different histori-
cal cohorts indicating a therapeutic effect of extended
lymphadenectomy [93, 95]. In addition, survival may also
be increased by treating node-positive patients with sys-
temic chemotherapy, in either a neoadjuvant or adjuvant
setting [96]. These reasons underline the importance of
accurate lymph node staging in bladder cancer patients. To
date, the value of pelvic lymphadenectomy is undisputed
for muscle-invasive bladder cancer. However, controversy
exists on the extent of lymphadenectomy and the minimum
number of nodes required for adequate lymphadenectomy,
since lymph drainage from the bladder shows a wide
variation and contralateral drainage is frequent [97–100]
Moreover, single node metastasis may occur outside the
known and accepted templates (e.g., along the common
iliac and presacral areas) [100–102]. A LN mapping study
using SPECT/CT after radiocolloid administration in 60
patients showed radioactive nodes in the external iliac
(30 %), the obturator fossa (25 %), the internal iliac
(26 %), the common iliac (15 %) and the para-aor-
tic/paracaval (4 %) region [100]. This means that extended
nodal dissection would have included 92 % of the active
nodes, and a more limited resection of external and
obturator template would have only included 50 % of the
radioactive lymph nodes [100]. SN biopsy may provide a
minimally invasive technique with the ability to identify
potential tumour-positive nodes outside the field of exten-
ded lymphadenectomy. Interestingly, even extended lym-
phadenectomy followed by histologic examination may
have its limits as approximately one-third of patients with
pathologically staged pN0 bladder cancer show micro-
metastases in LNs when molecular tools are used for
staging [103–105]. Consequently, there might also be a
role for SN mapping as a tool to improve nodal staging by
selecting lymph nodes for ultrastaging, e.g., using serial
sectioning and additional immunohistochemistry or reverse
transcriptase (RT)-PCR [106, 107]. Last, one report has
proposed the use of SN biopsy to harvest T-cells for
immunotherapy for bladder cancer [108].
The concept of SN biopsy was introduced to bladder
cancer in 2001 [109]. Methodologically, various tracer
injection techniques have been investigated, since both
intraoperative and transurethral injection may yield dif-
ferent draining patterns [100, 110]. The recommended
method is injection via a transurethral approach into the
detrusor muscle, in four different sites adjacent to the
visible bladder tumour [111]. In a recent study by
Schaafsma et al. comparing the different injection tech-
niques, cystoscopic injection with distension of the bladder
also appeared to be optimal, allowing for detection of the
SN in 11 out of 12 patients in this group (92 % detection
Fig. 4 Following
administration of the hybrid
tracer ICG-99mTc-nanocolloid
in both lobes of the prostate,
transversal SPECT/CT
(a) shows iliac and presacral
sentinel nodes, which are
subsequently removed by means
of a robot-assisted procedure
(b–d)
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rate). However, in this study only ICG was used and no
preoperative lymphatic imaging was possible [112]. Most
studies exploring SN mapping in bladder cancer used
radioactive colloids and lymphoscintigraphy using a simi-
lar injection technique [100, 109, 113]. The use of radio-
colloids also allows for preoperative SPECT/CT, which
can provide a useful road map to guide urologists during
the operation [114]. Intraoperative SN identification has
mostly been performed in an open surgery setting guided
by gamma-probes (and followed by extended pelvic lym-
phadenectomy). However, with the advent of minimally
invasive (laparoscopic/robot-assisted) approaches, newer
techniques for intraoperative SN detection such as the use
of a portable gamma camera and NIR fluorescence imaging
have also emerged [72, 82, 112, 115].
Taken together, the available studies report SN detection
rates ranging from 81 to 92 %. Initial validation studies
reported false-negative rates as high as 19 % [113]. These
numbers form the basis of the persisting concerns around
SN biopsy for bladder cancer as stated in the EAU
guidelines [116], yet the numbers are comparable with the
initial experiences in penile cancer, and more recent studies
have shown higher sensitivity rates [105]. Nevertheless, the
relatively high false-negative rates, the complexity of
injection and additional need of an extended nodal dis-
section may explain the limited use of the SN procedure for
bladder cancer management. Although SN biopsy for
bladder cancer is still in the early development phase, new
technologies such as portable gamma cameras, intraoper-
ative navigation and hybrid/NIR fluorescent tracers may
provide more insights into actual lymphatic drainage pat-
terns and in turn, help reduce the number of false-negatives
cases.
Renal cell cancer
Renal cell cancer (RCC) is the 8th most common malig-
nancy in Europe and the incidence is rising [117]. The
management of early stage RCC has traditionally been
surgical, and nephrectomy or nephron-sparing strategies
are often curative at this stage of the disease [118]. Even
when patients present with metastases, nephrectomy and
metastasectomy may be beneficial in selected cases
[119, 120]. Metastatic spread has been shown to have a
high correlation with tumour size and the widespread use
of ultrasound examination of the abdomen and increasing
use of whole-body screening (with CT or MRI) has led to
more small renal tumours being diagnosed [121–123]. This
stage shift may result in an increasing number of patients
with early lymph node metastases, who, in contrast to
historical data, may benefit from removal of these lesions
[124, 125]. SN biopsy could have both a prognostic and
therapeutic role in identifying and removing nodal disease
in patients without distant metastases. Another reason for
the interest in RCC SNs is the possibility within these
nodes to harvest T-lymphocytes for preparation and rein-
jection for the novel approach of autologous adoptive
immunotherapy [126]. In addition, the introduction of tar-
geted agents has revived interest in adjuvant treatment
concepts which also warrants accurate lymph node staging
[127].
Since RCC has a well-recognised haematogenous spread
and an unpredictable lymphatic drainage, the role of lymph
node dissection in RCC remains controversial [124]. The
general notion is that the draining lymph nodes from RCC
are in the hilar region, branching off into the paracaval,
inter-aortocaval or para-aortic retroperitoneal lymph nodes
(depending on the tumour side). However, the lymphatic
drainage of renal tumours may not always follow the
known pattern, as has frequently been found for other
tumour entities [128]. SN mapping offers the opportunity
to identify such aberrant lymphatic drainage patterns in
RCC.
After its initial feasibility was shown in porcine models
by Bernie et al., the first pilot study exploring SN biopsy
for RCC in humans was published by Bex et al. in 2010
[129, 130]. 99mTc-nanocolloid was injected percutaneously
into the renal tumour (\10 cm = cT1a/b-cT2a) guided by
ultrasound or CT, followed by lymphoscintigraphy and
SPECT/CT. The use of a portable gamma camera may
assist tracer injection and help to modify/repeat the injec-
tion procedure in case radioactivity is detected outside the
tumour and the kidney (Fig. 5). This approach led to suc-
cessful SN identification in six of eight patients. Following
a similar protocol, Sherif et al. detected 32 SNs in 10 of 11
patients in 2011 [126]. In a later follow-up study from Bex
et al. expanding the cohort to 20 patients SN visualisation
was possible in 70 % of cases. 2 of 20 patients had SNs
outside the retroperitoneal region [131]. The absence of
lymphatic drainage on imaging in 30 % of patients is of
concern, in relation to a potential clinical application of this
technique. This may be caused by lack of drainage of the
radiocolloid through lymphatic vessels. Alternatively, the
radiocolloid may have drained directly into the thoracic
duct without any interposition of a lymph node, as has been
proposed in a cadaver study by Assouad [132] and visu-
alised in a recent study using SPECT/CT [133]. Intraop-
erative detection of SNs in RCC has been performed during
open, and laparoscopic procedures and is generally carried
out guided by a gamma-probe. Patent blue is not frequently
used because of its limited contribution [126]. In the
published series by Bex et al., one patient had two tumour-
positive SNs at histopathology. The fact that all other
excised lymph nodes during retroperitoneal lymph node
dissection were tumour negative confirms the feasibility of
SN procedure in RCC patients, although more extensive
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research is needed to further substantiate the diagnostic and
therapeutic value of renal SN biopsy. Until then (extended)
lymph node dissection still remains the management of
choice in clinically node-positive patients without distant
metastases [116].
Testicular cancer
Testicular cancer is the most frequent malignancy in
young men, and the incidence has risen by almost 100 %
in the past 20 years. At the time of diagnosis, approxi-
mately two-thirds of patients have clinical stage I disease
[134]. The management of regional lymph nodes in stage
I testicular cancer generally consists of a surveillance
policy with intensive, frequent follow-up visits and costly
examinations since occult metastases are present in less
than 20 % of patients. The SN approach could potentially
aid in selecting patients with lymph node metastases so
that they can be treated at an early stage, while preventing
unnecessary treatment for those patients without metas-
tases. Furthermore, this could potentially save CT scans
(and radiation exposure) for 80 % of patients with stage I
cancer and reduce the number of patients maintained in
follow-up.
The use of SNs in testicular cancer is a relatively new
concept and experience with the application is limited
[135–138]. All published studies used radiocolloids as SN
tracer. In the initial feasibility study by Tanis et al. in 2002,
preoperative lymphatic mapping was performed using
planar lymphoscintigraphy [135]. While funicular tracer
administration showed only lymph node uptake in the
inguinal region (which does not reflect the actual testicular
tumour drainage pattern), intratesticular administration
resulted in visualisation of retroperitoneal SNs in accor-
dance with known drainage patterns. Following these
footsteps, a group from Japan demonstrated a detection rate
of 95 % in 22 stage I testicular cancer patients in 2005
[137]. Although lymphatic drainage of the testis is mainly
directed towards the areas along the aorta and vena cava,
aberrant drainage has also been observed [138]. The
identification of these SNs in relation to the anatomical
structures can be difficult using two-dimensional (2D)
lymphoscintigraphy alone. SPECT/CT can provide useful
anatomic information about the location of SNs and its
improved sensitivity and added third dimension may also
lead to the detection of additional SNs (Fig. 6). To date,
one study evaluating the use of SPECT/CT for preoperative
SN localisation in testicular cancer has been published.
Fig. 5 Sentinel node in renal-cell carcinoma. Following needle
insertion under ultrasound guidance (a, b) 99mTc-nanocolloid is
administered into the tumour (c). Transversal SPECT/CT (d) shows a
paracaval sentinel node, which is removed by means of laparoscopy
assisted with a portable gamma camera (e)
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SPECT/CT enabled accurate localisation of the SNs and
provided anatomical reference points to plan their laparo-
scopic retrieval [138].
In spite of the fact that SN biopsy for testicular cancer
was shown to be feasible, large-scale randomised clinical
studies to validate and assess the added benefit of the
approach are still lacking. This may be partially due to the
fact that patients are usually referred to tertiary/specialised
centres after orchidectomy has already been performed,
thus after removal of the potential injection site. More
importantly, the need for improvement of staging in stage I
testicular cancer is not pressing, with 5- and 10-year
overall cancer-specific survival rates approaching 100 %
[139]. On top of this, the use of adjuvant chemo and
radiotherapy in case of suspected lymphatic dissemination
at follow-up achieve very low recurrence rates and chemo-
sensitivity among relapse patients is high, which is why SN
biopsy does not currently have a role in lymph node
mapping in testicular cancer in the EAU guidelines [139].
Concluding Remarks
Throughout the years, the uro-oncological field has por-
trayed a pivotal role in the development of the SN concept,
resulting in a well-established role of SN biopsy in penile
cancer. Although its feasibility in prostate cancer has
repeatedly been demonstrated and its potential value is
increasingly being recognised, conclusive prospective
clinical data as well as consensus on methodology and
patient selection is still lacking. For bladder, renal and
testicular cancer, only few studies have been published and
concerns around high false-negative rates remain. Recent
advances such as hybrid tracers and novel intraoperative
detection tools such as fluorescence- and portable gamma
imaging will hopefully encourage prospectively designed
clinical trials which can substantiate the potential of the SN
approach in becoming an integral part of staging in uro-
logical malignancies.
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Fig. 6 Lymphatic mapping in testicular cancer after injection of
99mTc-nanocolloid in the left testicle. Early (a) and delayed (b) planar
images showing lymphatic tract visualisation and uptake in various
lymph nodes along the lymphatic duct. On SPECT/CT with volume
rendering (c) three sentinel nodes are indicated (arrows) correspond-
ing to localisations in para-aortic (d), funicular (e) and inguinal
(f) basin
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